Related by context. All words. (Click for frequent words.) 70 multicenter Phase II 67 HORIZONS AMI trial 67 phase IIIb 66 BARI 2D 66 viral kinetic 66 randomized controlled multicenter 66 ENDEAVOR IV 66 EVEREST II 66 prospective multicenter randomized 66 ENDEAVOR III 65 prospective randomized multicenter 65 RE LY ® 65 Phase IIb III 65 TASKi2 65 multicenter prospective 65 ExTRACT TIMI 65 REALITY Trial 65 MADIT II 65 MEND CABG II 65 phase IIb clinical 65 Multicenter Automatic Defibrillator Implantation 65 Phase Ib clinical 65 ROCKET AF 65 phase IIb study 65 TAXUS VI 64 deforolimus 64 SYNTAX trial 64 CARE HF 64 SUCCEED trial 64 trastuzumab emtansine T DM1 64 TRA 2P 64 TAXUS IV 64 BRIM2 64 PREVENT IV 64 neratinib 64 LUMINATE 64 Phase IIIb study 64 CALGB 64 multicenter clinical 64 ToGA 64 EXPLORE Xa 64 Phase 2b kidney transplant 63 Phase IIIb clinical 63 Phase Ib II 63 prospective multicenter 63 PRIMO CABG 63 treatment naive genotype 63 placebo controlled Phase III 63 ACCORD Lipid 63 ENESTnd 63 multicenter phase 63 ABSORB trial 63 multicenter randomized controlled 63 placebo controlled multicenter 63 PRIMO CABG2 63 APEX PD 63 randomized Phase IIb 63 AVADO 63 BRIM3 63 placebo controlled clinical 63 CHAMPION PCI 63 elotuzumab 63 TAXUS V 63 midstage clinical 63 PERSEUS 63 PROactive study 63 antiretroviral naïve 63 PROTECT AF 63 Phase 1a clinical 63 BR.# 63 RE LY 63 phase IIa clinical 63 angiographic outcomes 63 Phase III ADT 63 MEND CABG 62 HORIZONS AMI 62 ONTARGET 62 clevidipine 62 HF ACTION 62 EmbraceAC 62 Carotid Revascularization Endarterectomy vs. 62 randomized Phase 2b 62 subanalysis 62 BCIRG 62 GENASIS 62 NEVO RES 62 TASKi3 62 TRITON TIMI 62 AVOREN 62 ACRIN 62 prospective multicentre 62 MERLIN TIMI 62 CALGB # [002] 62 ALN VSP Phase 62 VADT 62 nonrandomized 62 EURIDIS 62 CLARITY study 62 confirmatory clinical 62 TG MV 62 SIMPADICO 62 PROSTVAC TM 62 phase IIb trial 62 ICON7 62 EchoCRT 62 oral deforolimus 61 HCV SPRINT 61 fidaxomicin Phase 3 61 placebo controlled dose escalation 61 NSABP B 61 pivotal bioequivalence 61 REVIVE Diabetes 61 Phase Ib IIa 61 NATRECOR ® 61 APEX AMI trial 61 GetGoal Phase III 61 CAPRIE 61 ACUITY trial 61 dirucotide MBP# 61 SPIRIT FIRST 61 APPRAISE 61 LUX Lung 61 ongoing Phase 1b 61 prospective observational cohort 61 CYPHER Stent 61 AIM HIGH 61 blinded randomized placebo controlled 61 PFO migraine 61 Phase 1b clinical trials 61 RSD# oral 61 MIST II 61 Phase Ib study 61 ECASS 61 NSABP C 61 landmark ATHENA 61 multicenter Phase III 61 controlled multicenter Phase 61 prospective nonrandomized 61 sNDA submission 61 multicenter Phase 61 Raloxifene Evaluation MORE 61 ENGAGE AF TIMI 61 multicenter multinational 61 NO# [002] 61 Augment Injectable 61 MYTHOS trial 61 randomized Phase III 61 Prostate Lung Colorectal 61 double blinded randomized 61 RESOLUTE clinical 61 galiximab 61 Clinical Antipsychotic Trials 61 Phase IIB 61 Phase IIa trial 61 MADIT CRT 60 multicenter randomized clinical 60 Prospective Randomized 60 DASISION 60 rALLy clinical trial 60 MAGE A3 ASCI 60 Phase #b/#a 60 Phase IIIb 60 Phase III VISTA 60 ACCEDE 60 AVERROES 60 oral ridaforolimus 60 Phase III metastatic melanoma 60 trastuzumab DM1 T DM1 60 SCD HeFT 60 SPIRIT IV 60 OLYMPIA registry 60 fosbretabulin 60 phase IIb 60 ADVANCE PD 60 ALSYMPCA 60 ug dose 60 SWOG 60 MADIT 60 Phase III AFFIRM 60 metastatic HRPC 60 Endeavor drug eluting 60 Phase 1b trial 60 PROSTVAC ® 60 EDEMA3 trial 60 Intervention Effectiveness 60 controlled multicenter 60 PROTECT II 60 multicentre prospective 60 recurrent malignant glioma 60 ENDEAVOR II 60 huC# DM4 60 EDEMA3 60 STRIDE PD 60 dose escalation phase 60 phase Ib 60 phase IIa 60 RE LY trial 60 NCIC CTG 60 CUSTOM II 60 TACI Ig 60 Phase 2a clinical 60 Zemplar Capsules 60 XL# XL# XL# 60 Sorafenib HCC Assessment 60 R# #mg BID 60 EXPAREL ™ 60 number NCT# ClinicalTrials.gov 60 retrospective cohort study 60 CUSTOM III 60 pain palliation 60 NATRECOR R 60 ABSORB clinical 60 thorough QT 60 COSIRA trial 60 Screening Trial DMIST 60 multicenter placebo controlled 60 novel oral anticoagulant 60 Phase #b/#a clinical 60 PEARL HF 60 observational cohort study 60 prospective observational studies 60 Edwards SAPIEN valve 60 Randomized controlled 60 Acute Coronary Syndromes 60 Multicenter 60 multicenter randomized placebo controlled 60 randomized discontinuation 60 Phase IIb clinical 59 Amrubicin 59 Phase 2b randomized 59 multicentre randomized 59 bicifadine 59 GRAVITAS trial 59 underwent CABG 59 BLOOM Behavioral modification 59 VESTASYNC 59 secondary efficacy endpoint 59 Randomized Evaluation 59 tramiprosate Alzhemed TM 59 RE SURGE 59 Val HeFT 59 Stage IIIb 59 CRLX# 59 SABCS 59 everolimus eluting stents 59 retinal vein occlusion induced 59 Dacogen injection 59 retrospective cohort 59 Matrix Phase 2b 59 TAXUS ATLAS 59 double blinded placebo 59 Dr. Kandzari 59 Phase Ib IIa clinical 59 Intervention Effectiveness CATIE 59 BioMatrix TM 59 TMC# C# 59 Gynecologic Oncology Group 59 randomized multicenter 59 relapsed MM 59 recurrent glioblastoma multiforme 59 GAMMAGARD 59 PLCO 59 pharmacokinetics PK 59 dose escalation clinical 59 dose escalation Phase 59 ZACTIMA 59 trial evaluating PRX# 59 GOUT 59 Phase IIb randomized 59 evaluating REVLIMID 59 OvaRex ® MAb 59 CLARITY TIMI 59 EMPHASIS HF trial 59 OvaRex MAb 59 preclinical efficacy 59 Tesmilifene 59 evaluating mipomersen 59 ENDEAVOR IV clinical 59 pharmacokinetic PK 59 bepotastine besilate nasal spray 59 Phase III ThermoDox 59 alvespimycin 59 treatment naïve genotype 59 CAMMS# 59 ZoMaxx 59 ASTEROID 59 Phase #/#a 59 rALLy trial 59 NSABP 59 subcutaneous PRO 59 TEMSO 59 NEVO 59 CIMZIA TM certolizumab pegol 59 PRECiSE 59 Androxal TM 59 unblinded 59 CALERIE 59 MelaFind pivotal 59 morphometric vertebral fractures 59 PRESEPT 59 prospective randomized placebo 59 prospective randomized controlled 59 Proellex TM 59 Phase 1b 59 Edge STudy 59 Xelox 59 Renal Cell Carcinoma RCC 59 NCCTG 59 pharmacokinetic pharmacodynamic 59 JAK inhibitor 59 Phase III randomized 59 zotarolimus eluting stent 59 MGd 59 ASCEND HF 59 pharmacokinetic PK study 59 ThermoDox ® clinical 59 Phase III multicenter 59 sunitinib malate 59 multicenter clinical trials 59 Phase #/#a trial 59 Phase III psoriasis 59 FAME Study 59 IMC #B 59 Tumor Response 59 MKC# MKC# PP 59 PCI ExTRACT TIMI 58 Initiated Phase 58 gefitinib Iressa 58 Medidur TM FA 58 NV1FGF 58 HCV RESPOND 2 58 RELOVAIR ™ 58 efficacy endpoint 58 GEM OS1 58 CURRENT OASIS 7 58 Digital Mammographic Imaging 58 papillary renal cell carcinoma 58 teriflunomide 58 CR# vcMMAE 58 GEM OS2 58 SUTENT ® 58 COU AA 58 Randomized Phase II 58 null responder HCV 58 LibiGel Phase III 58 PRECISE trial 58 Thorough QT 58 prospectively stratified 58 substudy 58 PEG SN# 58 Vascugel ® 58 ongoing Phase IIIb 58 APEX AMI 58 randomized multicenter trial 58 UVIDEM 58 Prostate AdenoCarcinoma Treatment 58 prelicensure 58 PreCISe study 58 arzoxifene 58 durable pain palliation 58 HPTN 58 UPLYSO 58 Vascular Wrap 58 forodesine 58 Sibutramine Cardiovascular Outcomes 58 volociximab 58 ORAL Sync 58 Phase IIb clinical trials 58 prognostic variables 58 prospectively defined 58 NICE SUGAR 58 Screening Trial 58 EOquin TM phase 58 dose escalation trial 58 KRAS mutations occur 58 RECORD1 58 REG2 58 Subgroup analysis 58 active comparator 58 multicenter randomized Phase 58 zotarolimus 58 everolimus eluting stent 58 IMPACT DCM 58 HYVET 58 cediranib 58 crizotinib PF # 58 clinical pharmacology studies 58 Phase III HEAT 58 PERSEUS clinical program 58 TransVax ™ 58 GERD migraine headaches 58 CINQUIL 58 SYNTAX 58 GSK# [001] 58 Phase IIIB IV 58 evaluating tivozanib 58 label multicenter 58 Teriflunomide 58 RTOG 58 atrasentan 58 Pivotal Clinical Trial 58 IMA# 58 Phase 2a trial 58 Long Lesion 58 Oral NKTR 58 Primary endpoints 58 registrational Phase 58 PSMA ADC 58 ZOLINZA 58 Enzastaurin 58 dacarbazine chemotherapy 58 CATIE AD 58 BrainGate TM 58 Temsirolimus 58 Aflibercept 58 prospective observational 58 HyQ 58 enzastaurin 58 budesonide foam 58 AIR CF1 58 ORBIT II 58 p# biomarker 58 Tarceva TM 58 Clinicaltrials.gov 58 AIR2 Trial 58 dose dose escalation 58 Ascendra 58 riociguat 58 subgroup analyzes 58 Trastuzumab DM1 58 Acute Decompensated Heart Failure 58 basal bolus regimen 58 USpella 58 melphalan prednisone 58 PEARL SC 58 ATACAND 58 placebo controlled Phase 58 CHARM Added 58 SPIRIT III 58 INSPIRE Trial Phase III 58 Allovectin 7 ® 58 TMC# [002] 58 COSTAR II 58 ARCOXIA 58 HGS ETR2 58 BRILINTA 58 Sapien valve 57 CIMZIA ™ 57 IL# PE#QQR 57 Phase 1b clinical 57 bevirimat Study 57 aflibercept 57 DAPT Study 57 HDL Selective Delipidation 57 CaPSURE 57 Vitaxin 57 glufosfamide 57 Trial ASCOT 57 NP2 Enkephalin 57 ponatinib 57 randomized controlled Phase 57 MADIT CRT trial 57 intradermal injections 57 Phase 2b RESTORE CLI 57 Institute DCRI 57 Acute Ischemic Stroke 57 antiangiogenic therapy 57 severe hypercholesterolemia 57 LHRH receptor positive 57 fostamatinib 57 investigational protease inhibitor 57 Refractory Angina 57 randomized blinded 57 Edwards SAPIEN 57 DEB# 57 blinded randomized controlled 57 irbesartan 57 docetaxel Taxotere R 57 definite stent thrombosis 57 SORT OUT III 57 HuMax EGFr 57 Group RTOG 57 longitudinal cohort 57 mITT population 57 Phase Ib 57 Targretin capsules 57 randomized multicenter Phase III 57 PROMUS Element Stent 57 ONCONASE R 57 registrational 57 mg/m2 cohort 57 ascending dose 57 Urocortin 2 57 abiraterone acetate 57 Phase 2b clinical trials 57 Phase IIa trials 57 Azedra 57 dose cohort 57 Dialysis Outcomes 57 ZYBRESTAT fosbretabulin 57 Kaplan Meier analysis 57 Phase 2b study 57 GENASIS clinical 57 Phase III placebo controlled 57 pertuzumab 57 MIVI TRUST 57 initiated Phase Ib 57 unblind 57 DSMB recommended 57 iniparib BSI 57 clinico pathological 57 genotypic resistance 57 budesonide MMX Phase III 57 EMPOWER ™ 57 Zenvia ™ 57 #mg QD [002] 57 VITAL Trial 57 Aryplase 57 Ovarian PLCO Cancer 57 DIRECT Trial 57 randomized controlled clinical 57 NOX E# 57 CONQUER OB 57 STEALTH C 57 Radiation Therapy Oncology 57 DU #b 57 multicenter randomized double 57 refractory CLL 57 AERx iDMS 57 Edwards SAPIEN XT 57 Eliquis 57 axitinib 57 induced macular edema 57 multinational multicenter randomized 57 AIMM trial 57 ADVEXIN therapy 57 ARBITER 6 57 retrospective observational study 57 Rheos System 57 dirucotide 57 Myocardial Infarction Study 57 RRMS patients 57 lorcaserin Phase 57 INCB# [001] 57 paclitaxel eluting stent 57 AIR CF2 57 RIO Lipids 57 evaluating Actimmune 57 prasugrel Effient 57 IMC A# 57 PDX pralatrexate 57 Phase III confirmatory 57 secondary efficacy endpoints 57 CIMZIA TM 57 nab paclitaxel 57 TAXUS Stent 57 NCT# ClinicalTrials.gov 57 opioid naive 57 CA9 SCAN 57 Endeavor Resolute DES 57 Multicenter AIDS 57 mg BID dose 57 ALLHAT 57 azilsartan medoxomil 57 XIENCE V Everolimus Eluting 57 NEUVENGE 57 Multicenter Phase 57 Phase 2b clinical 57 Endovascular Valve Edge 57 CARDIA study 57 elacytarabine 57 Afatinib 57 ARB telmisartan 57 modified REGENESIS Phase IIb 57 lorvotuzumab mertansine 57 varespladib 57 SYMMETRY trial 57 PANVAC VF 57 Phase III Psoriasis 57 Allovectin 7 57 regorafenib 57 MVax R 57 multicentre randomized double 57 PORxin TM platforms 57 motesanib 57 Diabetic Macular Edema 57 LibiGel testosterone gel 57 YONDELIS 57 DF HCC 57 Deforolimus 56 PA# [002] 56 pegylated interferon alfa 2b 56 Hedgehog Pathway Inhibitor 56 pharmacodynamic markers 56 ER CHOP 56 evaluable subjects 56 Pharmacokinetic parameters 56 Begins Clinical Trial 56 desvenlafaxine succinate 56 Aplidin 56 sirolimus eluting 56 COPERNICUS 56 COMFORT II 56 GV# [001] 56 Phase 1a 56 ASCO abstract 56 BrachySil TM 56 YERVOY 56 Tanespimycin 56 transapical 56 Meta analyzes 56 Phase IIb 56 THALOMID 56 Ereska 56 Trandolapril 56 HCD# [002] 56 comparator arm 56 EINSTEIN DVT 56 RIO Diabetes 56 prospective longitudinal 56 Onrigin 56 ANCHOR trial 56 L BLP# 56 vidofludimus 56 visceral metastases 56 NEO3 56 longitudinal observational study 56 pharmacodynamic effects 56 randomized discontinuation trial 56 symptomatic VTE 56 OMAPRO ™ 56 acyclovir Lauriad R 56 XIENCE V Stent System 56 ASSERT 56 WallFlex Biliary RX 56 LymphoStat B belimumab 56 human IgG1 monoclonal 56 pomalidomide 56 Risk Stratification 56 vismodegib 56 Ovarian Cancer Screening 56 STEP BD 56 opioid induced bowel dysfunction 56 Sipuleucel T 56 hoFH 56 bardoxolone 56 relapsed refractory multiple myeloma 56 stage IIIb IV 56 thromboembolic complications 56 TAXUS paclitaxel eluting coronary 56 prospectively randomized 56 LibiGel ® testosterone gel 56 genomic biomarker 56 initiate multicenter 56 Pharmacokinetic 56 alemtuzumab Campath 56 blinded randomized 56 REG1 56 Aurexis 56 romidepsin 56 deCODE AF TM 56 PrevOnco 56 Combination REOLYSIN R 56 TAXUS Liberte Stent 56 trodusquemine 56 PRECISE Trial 56 EGS# 56 efficacy tolerability 56 Omacetaxine 56 Medtronic CoreValve 56 BioNumerik 56 Quinamed 56 Completes Patient Enrollment 56 FOLPI 56 Ixempra 56 #:# randomization 56 prospective multicenter study 56 Stenting Trial CREST 56 Achieves Primary Endpoint 56 preclinical pharmacokinetic 56 unblinding 56 National Emphysema Treatment 56 Study ARIC 56 Hepatocellular Carcinoma HCC 56 longitudinal cohort study 56 REVIVE TA 56 initiate Phase IIb 56 preclinical pharmacology 56 FOLFOX6 chemotherapy regimen 56 GW# [003] 56 Spine Patient Outcomes 56 CURE AF 56 Zevalin consolidation 56 dosing cohorts 56 label multicenter randomized 56 Unstable Angina 56 Ophena 56 FOLOTYN ® 56 Initiates Phase III 56 Embolic Protection Device 56 telaprevir dosing 56 metaglidasen 56 fidaxomicin Phase 56 PROSTVAC VF 56 composite endpoint 56 biliary tract cancer 56 unique alkylating agent 56 phase 2a 56 ILUVIEN 56 virus HCV protease inhibitor 56 Neuradiab TM 56 tolerability pharmacokinetics 56 meta regression 56 DermaVir Patch 56 brivaracetam 56 CHAMPION PLATFORM 56 NeuroFlo 56 Gattex 56 evaluating satraplatin 56 TLK# 56 Bicifadine 56 BLA submission 56 CAMPATH 56 Phase III pivotal 56 Advaxis Phase 56 ELACYT 56 Diabetes ACCORD 56 HIV coinfected 56 phase III isavuconazole 56 BENICAR HCT 56 Cypher Stent 56 MVA MUC1 IL2 56 ischemic cardiomyopathy 56 PDE# inhibitors 56 postmenopausal osteoporotic women 56 sunitinib Sutent 56 MGCD# clinical trials 56 cortical stimulation 56 unstable angina UA 56 ILLUSTRATE 56 OPT CHF 56 Pivotal Trial 56 brivanib 56 Corlux 56 ORENCIA ® 56 Patient Outcomes 56 paclitaxel eluting stents 56 Thrombolysis 56 BrachySil ™ 56 Genz # 56 Heterozygous Familial Hypercholesterolemia 56 events SAEs 56 Zenvia Phase III 56 CLL8 56 Phase III randomized controlled 56 antibody MAb 56 randomized #:#:# 56 Vernakalant 56 Prosaptide 56 Neuradiab 56 REGENESIS Phase IIb 56 Motesanib 56 rindopepimut 56 IIa clinical 56 Breaking Clinical Trials 55 clazosentan 55 OncoVEX 55 multicentre study 55 Omnitarg 55 Resolute DES 55 Alequel 55 Sirolimus eluting Coronary Stent 55 GRN# 55 concurrent chemoradiation 55 Acute Myocardial Infarction 55 PLCO trial 55 Triapine 55 ADMIRE HF 55 non valvular atrial 55 Traficet EN 55 eritoran 55 weekly subcutaneous injections 55 AFRS TM 55 peginesatide 55 Secondary efficacy endpoints 55 antiretroviral naive 55 fallopian tube cancers 55 Safinamide 55 motesanib diphosphate 55 Health Initiative Observational 55 OVATURE trial 55 CLIRS 55 oral rivaroxaban 55 BioSante LibiGel Phase III 55 Serious Adverse Events 55 trastuzumab Herceptin R 55 tanespimycin 55 HGS# 55 multicenter trials 55 Hsp# Inhibitor 55 trials RCTs 55 REMINYL ® 55 CAPACITY trials 55 midstage studies 55 TRIST study 55 Cimzia TM 55 plus prednisone 55 Daclizumab 55 multicenter randomized Phase III 55 liposomal formulation 55 tumor histology 55 HCV NS5B polymerase 55 retrospectively analyzed 55 PROPEL trial 55 Ozarelix 55 receptor tyrosine kinase inhibitor 55 tolevamer 55 assessing T DM1 55 PF # [002] 55 fully bioabsorbable 55 AEGR 55 Maximum Tolerated Dose MTD 55 Clinical Outcomes Utilizing Revascularization 55 tesmilifene 55 PHX# 55 metaanalysis 55 Zybrestat 55 dacetuzumab 55 OvaRex R 55 sipuleucel T 55 EGFR mutation status 55 Pimavanserin 55 ASCO GI 55 metastatic hormone refractory 55 Initiates Enrollment 55 IMPROVE IT 55 cardio renal 55 EOquin TM 55 DSMB 55 EGFR HER2 55 European Sepsis Trial 55 Eluting Coronary Stent System 55 ENDEAVOR clinical 55 Randomized Clinical Trial 55 samalizumab 55 TBC# 55 CANCIDAS 55 PRE SURGE 55 RCW breast cancer 55 Solazed 55 Degarelix 55 IMPROVE HF 55 BioSTAR ® 55 Ophena TM 55 CRp 55 Nesiritide 55 taxane resistant 55 BST CarGel R 55 visilizumab 55 Nasdaq ONXX today 55 lomitapide 55 solithromycin 55 neoadjuvant treatment 55 Rigel R# 55 Feasibility Trial 55 Wisconsin Sleep Cohort 55 TAXUS TM 55 resectable pancreatic cancer 55 sorafenib tablets 55 placebo controlled clinical trials 55 Folfox 55 Dacogen decitabine 55 epoetin alpha 55 LymphoStat B TM 55 HER2 positive metastatic breast 55 Bowel Project NSABP 55 orally administered inhibitor 55 DNA methylation markers 55 RenalGuard System TM 55 BAY #-# 55 tremelimumab 55 Anturol TM 55 SPARCL 55 RESTORE CLI 55 EQUIP OB 55 PEG Interferon lambda 55 DAPT 55 ganetespib 55 FIX HF 5 55 Phase IIb trials 55 placebo controlled randomized 55 UA NSTEMI 55 maximally tolerated dose 55 florbetaben 55 #mg QD [001] 55 ACTEMRA TM 55 GSK# [002] 55 everolimus eluting 55 Delcath Phase III 55 Virologic 55 plasma pharmacokinetics 55 PROMUS Element Everolimus Eluting 55 Provacel 55 Levacor TM 55 Multivariate logistic regression 55 Azedra TM 55 OVATURE 55 hemodynamically significant 55 StemEx R 55 placebo PBO 55 rFVIIa 55 Pivotal Phase III 55 CLIRS trial 55 unstable angina pectoris 55 multicenter randomized 55 ruboxistaurin 55 vildagliptin 55 INTERHEART study 55 FDA defined valvulopathy 55 PROCHYMAL 55 pretransplant 55 Percutaneous Coronary Intervention 55 FluCAM arm 55 pharmacokinetic parameters 55 mertansine 55 afatinib 55 underwent liver transplantation 55 ancrod 55 cathepsin K inhibitor 55 PROactive Study 55 pharmacodynamics 55 SPRYCEL ® 55 Azedra ™ 55 Androgel R 55 confirmatory Phase 3 55 remission CR 55 confirmatory Phase III 55 ritonavir boosted 55 PrevOnco ™ 55 Amoxicillin PULSYS Phase III 55 neoadjuvant 55 KRN# 55 Virulizin ® 55 Systemic Sclerosis 55 eTag assays 55 phase III ACCLAIM 55 dose regimens 55 Prostate Cancer Prevention 55 Vascular Wrap TM 55 EMPHASIS HF 55 liver transplant recipients 55 doxorubicin docetaxel 55 dalteparin 55 Bayer HealthCare Onyx Pharmaceuticals 55 dosage regimens 55 AERAS-#/Crucell Ad# 55 randomized crossover 55 HQK 55 TIMI Study Group 55 HeFT 55 IMPACT DCM clinical 55 Pertuzumab 55 PRESEPT study 55 phase IIb III 55 relapsed MCL 55 coronary stent merged 55 cilengitide 55 drug eluting coronary stent 55 irinotecan cisplatin 55 histologically confirmed 55 Apixaban 55 coinfected patients 55 thorough QTc 55 meta analysis pooling 55 candidates Dyloject TM 55 Decompensated Heart Failure 55 Vectibix panitumumab 55 cisplatin vinorelbine 55 ABCSG 55 MedPulser 55 multivariate analyzes 55 ALGRX 55 unresectable malignant mesothelioma UMM 55 ELCAP 55 dietary questionnaires 55 midstage clinical trials 55 including eniluracil ADH 55 CIP ISOTRETINOIN 55 thetreatment 55 Randomized Controlled 55 iniparib 55 RESOLUTE 55 achieved statistical significance 55 controlled dose escalation 55 #th Annual Interscience 55 refractory AML 55 senicapoc 55 GORE TAG Device 55 XIENCE V demonstrated